Israel's Protalix BioTherapeutics Q3 revenue rises, driven by higher sales to Chiesi
PLX•PLX•PLX•PLX•Protalix BioTherapeutics said third-quarter revenue and net income rose year over year, driven mainly by higher sales to Chiesi. It expects 2026 revenue of $78 million to $83 million and said it expects to meet or exceed its revenue guidance.
Protalix BioTherapeutics reported higher third-quarter revenue and net income year over year. Growth was primarily driven by increased sales to Chiesi, partly offset by lower sales to Fiocruz and lower license and research and development revenue because fewer services were provided to Chiesi.
The company expects total 2026 revenue of $78 million to $83 million. It forecasts Elfabrio sales, excluding milestones, of $33 million to $35 million and Elelyso sales of $20 million to $23 million, and expects to meet or exceed its revenue guidance.
Third-quarter net income was $3.96 million, operating income was $4.05 million, pretax profit was $4.62 million, and earnings per share were $0.05.
